Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LM-302 plus gemcitabine as second-line therapy in CLDN18.2-positive unresectable pancreatic cancer (Phase II, single-arm, open-label)
ChiCTR2500108126Phase 2Not yet recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Aug 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tpx-4589 in pancreatic adenocarcinoma (PDAC), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Objective response rate (ORR). Planned start Aug 2025; status: not yet recruiting.
02
Drugs
tpx-4589
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on ChiCTR2500108126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500108126.